Search Results

ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into mainland China.

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company has entered into a strategic partnership with Sinopharm Group Co. Ltd. (“Sinopharm”) to strengthen its commercial capabilities and accelerate its commercialization transformation.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) today announced that TSB Therapeutics (Beijing) Co., Ltd. (“TSB Therapeutics”), a joint venture majority-owned by the Company, is partnering with Sinopharm Holding Co., Ltd.

The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning.

Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from ongoing preclinical research on the topical administration of a formulation of Provectus’s proprietary, pharmaceutical-grade, small molecule, rose bengal sodium (“RBS”) drug substance are being presented at the annual meeting of the Society for Investigative Dermatology (“SID”), to be held May 15-18, 2024 in Dallas, Texas.

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.